| Followers | 617 |
| Posts | 26966 |
| Boards Moderated | 0 |
| Alias Born | 08/12/2010 |
Friday, November 17, 2017 8:38:50 PM
Purdue Approaches States in Bid to Settle Opioid Claims
November 17, 2017
https://www.bloomberg.com/news/articles/2017-11-17/purdue-is-said-to-approach-states-in-bid-to-settle-opioid-claims
The Lawyer Who Beat Big Tobacco Takes On the Opioid Industry
We are talking 100's of billions in settlements possibly more. Pharma is in desperate need. Folks we have a proven on the market solution that aids in reducing and ultimately removing the need for opioid's.
“All the principle work has been in humans. So, the Nyloxin product is amazing. It’s non-addictive, no opiate, non-narcotic. In the last model, it outperformed morphine. It lasted six hours longer than morphine without any of the side effects,” explained Rik Deitsch, CEO of Nutra Pharma Corp. Additionally, since the dose of Nyloxin is so small compared to the dose of morphine required, the Nyloxin was considered to be approximately 600 times more potent than the morphine on a molecular basis.We have also stated that there are no contraindications in utilizing the Nyloxin with opiate drugs. In fact, since their mechanisms of action are so vastly different, we have seen a synergistic benefit.
It's out there and success stories are growing.
Billions folks and it's not just the billions pharma are having to pay. What about the revenue generator that is going away. That's the most painful aspect of it all to pharma. Not only paying out billions but losing much of their billion dollar opioid revenue generator. They need alternatives!!!
When the herd of cattle move away from opioid's and towards alternatives like Nyloxin (patent protected) all I can say is I hope folks are on board!!!
Its coming!!!!
Lets put this in perspective. If Nyloxin would be an alternative to just 1% of a 100's of billions in opioid revenue generation that equates to 1 billion for every 100 billion. This is the potential. IMHO from the results and success experienced by Nyloxin the potential is probably more massive than any of us could imagine. Talking about being in the right place at the right time!!! A fraction of a percent is HUGE!! I can only imagine a proper market cap if we had a fraction of a percent of the potential out there. Believe me, more than any of us have ever speculated! We are already endorsed by a big player in bio techs Jack Brewer of the Brewer Group. Folks we have credibility and a proven solution on the market! It doesn't get any better than that.
The Opioid crisis has just hit new levels of urgency for pharma.
We knew the lawsuits were coming but this has sped up in awareness in critical mass more than any of the pharma corp. really had anticipated.
Company's with proven alternatives to opioid's are in the right place at the right and will most definitely benefit. We are in the proverbial sweet spot!!!
ADDING AND HOLDING TIGHT!!!!!
November 17, 2017
https://www.bloomberg.com/news/articles/2017-11-17/purdue-is-said-to-approach-states-in-bid-to-settle-opioid-claims
The Lawyer Who Beat Big Tobacco Takes On the Opioid Industry
We are talking 100's of billions in settlements possibly more. Pharma is in desperate need. Folks we have a proven on the market solution that aids in reducing and ultimately removing the need for opioid's.
“All the principle work has been in humans. So, the Nyloxin product is amazing. It’s non-addictive, no opiate, non-narcotic. In the last model, it outperformed morphine. It lasted six hours longer than morphine without any of the side effects,” explained Rik Deitsch, CEO of Nutra Pharma Corp. Additionally, since the dose of Nyloxin is so small compared to the dose of morphine required, the Nyloxin was considered to be approximately 600 times more potent than the morphine on a molecular basis.We have also stated that there are no contraindications in utilizing the Nyloxin with opiate drugs. In fact, since their mechanisms of action are so vastly different, we have seen a synergistic benefit.
It's out there and success stories are growing.
Billions folks and it's not just the billions pharma are having to pay. What about the revenue generator that is going away. That's the most painful aspect of it all to pharma. Not only paying out billions but losing much of their billion dollar opioid revenue generator. They need alternatives!!!
When the herd of cattle move away from opioid's and towards alternatives like Nyloxin (patent protected) all I can say is I hope folks are on board!!!
Its coming!!!!
Lets put this in perspective. If Nyloxin would be an alternative to just 1% of a 100's of billions in opioid revenue generation that equates to 1 billion for every 100 billion. This is the potential. IMHO from the results and success experienced by Nyloxin the potential is probably more massive than any of us could imagine. Talking about being in the right place at the right time!!! A fraction of a percent is HUGE!! I can only imagine a proper market cap if we had a fraction of a percent of the potential out there. Believe me, more than any of us have ever speculated! We are already endorsed by a big player in bio techs Jack Brewer of the Brewer Group. Folks we have credibility and a proven solution on the market! It doesn't get any better than that.
The Opioid crisis has just hit new levels of urgency for pharma.
We knew the lawsuits were coming but this has sped up in awareness in critical mass more than any of the pharma corp. really had anticipated.
Company's with proven alternatives to opioid's are in the right place at the right and will most definitely benefit. We are in the proverbial sweet spot!!!
ADDING AND HOLDING TIGHT!!!!!
ALL POSTS are just my opinion! Never BUY/SELL stock based on only them! Perform your own DD and make your own decision!
Recent NPHC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/06/2026 09:10:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/25/2026 06:38:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/11/2026 07:22:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/17/2026 07:11:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/02/2026 06:52:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/23/2025 06:15:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/17/2025 10:08:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/24/2025 06:48:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/28/2025 08:02:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/23/2025 05:43:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2025 08:38:46 PM
